# BCAX — Bicara Therapeutics Inc · catalysts, narrative & risks

**Deep-research report — K3vl4r**  
**Symbols:** BCAX  
**Sources:** 16  
**Published:** 2026-10-11  
**Canonical:** https://app.k3vl4r.com/research/deep-research-bcax-bicara-therapeutics-inc-catalysts-narrative-risks-6965

---

# Bicara Therapeutics Inc. (Nasdaq: BCAX) — Point-in-Time Profile (as of 2026-10-11)

**Company snapshot:** Bicara Therapeutics is a clinical-stage biopharmaceutical company focused on bifunctional therapies for solid tumors. Its lead program is **ficerafusp alfa (BCA101)**, a first-in-class EGFR/TGF-β bifunctional antibody designed to break barriers in the tumor microenvironment [[1]](https://www.stocktitan.net/news/BCAX/), [[7]](https://finance.yahoo.com/healthcare/articles/bicara-therapeutics-announces-inducement-grants-123000327.html), [[9]](https://www.marketbeat.com/stocks/NASDAQ/BCAX/). The company is based in Boston/Cambridge, Massachusetts [[9]](https://www.marketbeat.com/stocks/NASDAQ/BCAX/), [[16]](https://stockanalysis.com/stocks/bcax/), [[17]](https://www.cnn.com/markets/stocks/BCAX). Shares traded near **$17.50** on October 9, 2026, with a market capitalization of approximately **$1.16B**, sitting in a 52-week range of $13.70–$30.99 [[9]](https://www.marketbeat.com/stocks/NASDAQ/BCAX/), [[16]](https://stockanalysis.com/stocks/bcax/), [[17]](https://www.cnn.com/markets/stocks/BCAX). *This is not investment advice.*

---

## Recent Catalysts (last ~1–3 months)

---

_Preview only. The complete multi-source deep-research report — full thesis, evidence, and citations — is available at https://app.k3vl4r.com/research/deep-research-bcax-bicara-therapeutics-inc-catalysts-narrative-risks-6965 (free to sign up)._
